MK677 – the ultimate secretagogue – what is all the hype?
-
Sports Technology Labs - Last Updated: March 7, 2024
Table of Contents
MK 677
MK677, also known as Ibutamoren, is not a SARM but a potent, orally-available, long-acting, selective non-peptide agonist of the ghrelin receptor that acts as a growth hormone secretagogue in vivo. In addition to its direct promotion of appetite, MK677 produces a sharp increase in human growth hormone (HGH) and insulin-like growth factor 1 (IGF-1) secretion, resulting in a sustained increase in plasma levels of these hormones without affecting cortisol levels .
Chemical formula of MK 677:
| C28H40N4O8S2 |
MK677 Health Research
Animal research has demonstrated that MK677 has the potential to increase muscle mass, bone density, and accelerate the growth of connective tissues. Medical studies on MK-677 reveal its potential to benefit individuals with low levels of HGH and IGF-1, such as adolescents and older subjects with growth hormone deficiency.
Research in Mice
Clinical Study
Ghrelin, a 28-amino-acid peptide hormone, is primarily released from gastric enteroendocrine cells and can be triggered by hunger.
Alzheimer’s disease (AD) is a prevalent form of dementia, and only a few studies have investigated the effects of ghrelin agonists or antagonists in animal models of AD, such as [d-Lys3]-GHRP-6.
However, a recent study evaluated the role of MK 677, a ghrelin agonist, in the levels of phosphorylation of the cyclic adenosine monophosphate (cAMP) response element binding protein (pCREB), responsible for cognitive functioning and neuronal survival.
MK 677 is also being investigated for its nootropic effects and its potential to protect the brain from Alzheimer’s disease.
As a ghrelin receptor agonist, MK677 is an active neuropeptide that crosses the blood-brain barrier and has been shown to improve REM sleep quality and protect the brain from β-Amyloid proteins in mice.
Thioflavin-S staining and immunohistochemical staining results suggest that MK-0677 administration attenuates Aβ deposition and Aβ-mediated pathologies in the neocortex of three-month-old 5XFAD mice.
Moreover, MK-0677 inhibited the decreased pCREB levels in the dentate gyrus of the hippocampus. Taken together, these findings suggest that MK-0677 may have potential in the treatment of early phase AD.
Researchers are studying MK677’s potential effects on skeletal muscle, connective tissue, and bone mineral density, as well as its impact on the hypopituitary testicular axis (HPTA) and testosterone levels.
More Research in Mice
One study conducted animal research on rats examined the effects of MK 677, administered orally to mice. Results showed that MK 677 can increase growth hormone levels at peak concentrations of serum GH by 1.8-fold compared to basal levels.
However, no growth-promoting effects were observed after 6 weeks in the study, as assessed by body weight, body length, width of tibia growth plate, and serum level of IGF-I. This suggests that prolonged use of MK-677 may lead to desensitization of the growth hormone receptor.
The mechanisms of this desensitization are not fully understood, but may involve increased expression of somatostatin in the hypothalamus. Side effects of this study were not documented other than this information given.
Because of this, further research is necessary to develop strategies to overcome this potential limitation of MK 677. Researchers must perform more studies on MK 677 and related products to find how the compound affects lean muscle, muscle and bone, cortisol levels, cholesterol levels, and GH levels more in mice to further expand knowledge regarding this compound.
What Benefits of MK 677 Are Researchers Studying and Why?
1. The mimics of Ghrelin to increase and sustain appetite, HGH, and IGF-1 levels.
2. Effects on skeletal muscle, connective tissue, and bone mineral density, bone density.
3. Effects on the hypopituitary testicular axis (HPTA) and testosterone levels.
4. The brain, central nervous system and β-Amyloid proteins in mice, as well as sleep quality.
5. MK 677 and research purposes of Alzeimer’s disease in mice.
AT THIS TIME, MK677 / IBUTAMOREN IS ONLY APPROVED FOR LABORATORY RESEARCH AND IS NOT SOLD FOR HUMAN CONSUMPTION.
Sale! 
Original price was: $119.99.$109.99Current price is: $109.99.
Where to buy MK677
A quick google search will reveal over 400 sources claiming to sell legit MK-677. Unfortunately many of these companies will have a decrease in customer services as they do not vet their raw materials or submit their products for third party testing.
Sports Technology Labs sells the highest quality SARMs guaranteed through strict quality control standards and every batch of their liquid MK 677 and Powdered MK 677 (Ibutamoren MK 677) are third-party tested by an American laboratory for minimum 98% purity, the standard used by Universities and Chemical Suppliers around the world.
Simply add products in the cart and begin research with the highest quality ibutamoren MK 677 in the industry.
Abuse Warning
It’s essential to note that MK677 is an investigational compound awaiting FDA approval and is not a dietary supplement.
Therefore, it’s essential to use caution when considering studying this or participating in clinical trials. Anecdotal reports and guides may not match those used in carefully designed medical research protocols.
Additionally, individual variables, comorbidities, and polypharmacy can contribute significantly to the risk of adverse effects which is why these products are to be used by medical professionals and researchers only.
Therefore, it’s essential to use caution when considering studying this or participating in clinical trials. Anecdotal reports and guides may not match those used in carefully designed medical research protocols.
Additionally, individual variables, comorbidities, and polypharmacy can contribute significantly to the risk of adverse effects which is why these products are to be used by medical professionals and researchers only.
Scientific References:
1. Patchett AA, Nargund RP, Tata JR, Chen MH, Barakat KJ, Johnston DB, Cheng K, Chan WW, Butler B, Hickey G (July 1995). “Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue”. Proceedings of the National Academy of Sciences of the United States of America. 92 (15): 7001–5. doi:10.1073/pnas.92.15.7001. PMC 41459. PMID 7624358.
2. Copinschi G, Van Onderbergen A, L’Hermite-Balériaux M, Mendel CM, Caufriez A, Leproult R, Bolognese JA, De Smet M, Thorner MO, Van Cauter E (August 1996). “Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men”. The Journal of Clinical Endocrinology and Metabolism. 81 (8): 2776–82. doi:10.1210/jcem.81.8.8768828. PMID 8768828.
3. Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM, et al. (December 1996). Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. The Journal of Clinical Endocrinology and Metabolism. 81 (12): 4249–57. doi:10.1210/jcem.81.12.8954023. PMID 8954023
4. Thorner MO, Chapman IM, Gaylinn BD, Pezzoli SS, Hartman ML (1997). “Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging”. Recent Progress in Hormone Research. 52: 215–44, discussion 244-6. PMID 9238854.
5. Chapman IM, Pescovitz OH, Murphy G, Treep T, Cerchio KA, Krupa D, Gertz B, Polvino WJ, Skiles EH, Pezzoli SS, Thorner MO (October 1997). “Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults”. The Journal of Clinical Endocrinology and Metabolism. 82 (10): 3455–63.
6. Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ (July 1999). “Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group”. Journal of Bone and Mineral Research. 14 (7): 1182–8. doi:10.1359/jbmr.1999.14.7.1182. PMID 10404019
7. Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ (March 2001). “Effect of alendronate and MK-677, individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women”. The Journal of Clinical Endocrinology and Metabolism. 86 (3): 1116–25. doi:10.1210/jcem.86.3.7294. PMID 11238495.
8. Jeong YO, Shin SJ, Park JY, et al. MK-0677, a Ghrelin Agonist, Alleviates Amyloid Beta-Related Pathology in 5XFAD Mice, an Animal Model of Alzheimer’s Disease. Int J Mol Sci. 2018;19(6):1800. Published 2018 Jun 18. doi:10.3390/ijms19061800
9. Lee, J., Kwon, A., Chae, H. W., Lee, W. J., Kim, T. H., & Kim, H. S. (2018). Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats. Yonsei Medical Journal, 59(10), 1174-1180.
10. Stabnov, L., Kasukawa, Y., Guo, R., Amaar, Y., Wergedal, J. E., Baylink, D. J., & Mohan, S. (2002). Effect of insulin-like growth factor-1 (IGF-1) plus alendronate on bone density during puberty in IGF-1-deficient MIDI mice. Bone, 30(6), 909-916.
More Posts To Explore
Share This Post
